

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended **September 30, 2018**

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File No. **000-55523**

**APPLIED BIOSCIENCES  
CORP.**

(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction of incorporation or organization)

None  
(I.R.S. Employer Identification No.)

**9701 Wilshire Blvd., Suite 1000  
Beverly Hills, California 90212**  
(Address of principal executive offices) (Zip Code)

**(310) 356-7374**  
(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (check one):

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
(Do not check if a smaller reporting company)		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act): Yes  No

APPLICABLE ONLY TO CORPORATE ISSUERS

As of November 9, 2018 there were 11,772,113 shares of common stock, \$0.00001 par value per share, outstanding.

**APPLIED BIOSCIENCES CORP.**  
**QUARTERLY REPORT ON FORM 10-Q**  
**FOR THE PERIOD ENDED SEPTEMBER 30, 2018**

**INDEX**

<u>Index</u>	<u>Page</u>
<b><u>Part I. Financial Information</u></b>	
<b><u>Item 1. Unaudited Condensed Consolidated Financial Statements</u></b>	
<u>Condensed Consolidated Balance Sheets as of September 30, 2018 (Unaudited) and March 31, 2018.</u>	4
<u>Condensed Unaudited Consolidated Statements of Operations for the three and six months ended September 30, 2018 and September 30, 2017.</u>	5
<u>Condensed Unaudited Consolidated Statements of Stockholders' Equity for the six months ended September 30, 2018.</u>	6
<u>Condensed Unaudited Consolidated Statement of Cash Flows for the six months ended September 30, 2018 and September 30, 2017.</u>	7
<u>Notes to Condensed Consolidated Financial Statements (Unaudited).</u>	8
<b><u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.</u></b>	14
<b><u>Item 3. Quantitative and Qualitative Disclosures About Market Risk.</u></b>	18
<b><u>Item 4. Controls and Procedures.</u></b>	18
<b><u>Part II. Other Information</u></b>	
<b><u>Item 1. Legal Proceedings.</u></b>	19
<b><u>Item 1A. Risk Factors.</u></b>	19
<b><u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</u></b>	19
<b><u>Item 3. Defaults Upon Senior Securities.</u></b>	19
<b><u>Item 4. Mine Safety Disclosures.</u></b>	19
<b><u>Item 5. Other Information.</u></b>	19
<b><u>Item 6. Exhibits.</u></b>	20
<b><u>Signatures</u></b>	21

## CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q of Applied Biosciences Corp., a Nevada corporation (the “Company”), contains “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: the possibility that we will not receive sufficient customers to grow our business, the Company’s need for and ability to obtain additional financing, other factors over which we have little or no control; and other factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”).

Our management has included projections and estimates in this Form 10-Q, which are based primarily on management’s experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the SEC or otherwise publicly available. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

**PART I—FINANCIAL INFORMATION****Item 1. Financial statements.****APPLIED BIOSCIENCES CORP.  
CONDENSED CONSOLIDATED BALANCE SHEETS**

	<b>September 30, 2018</b>	<b>March 31, 2018</b>
	(unaudited)	
<b>ASSETS</b>		
<b>Current Assets</b>		
Cash	\$ 6,924	\$ 60,934
Accounts receivable, net of allowance of nil and \$2,227 at September 30, 2018 (unaudited) and March 31, 2018, respectively	11,065	12,386
Inventory	51,672	29,074
Prepays and other current assets	54,455	124,455
<b>Total Current Assets</b>	<u>124,116</u>	<u>226,849</u>
Property and equipment, net	3,855	4,441
Equity investments	873,300	468,537
Other asset	5,500	5,500
<b>TOTAL ASSETS</b>	<u>\$ 1,006,771</u>	<u>\$ 705,327</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>Current Liabilities</b>		
Accounts payable	\$ 39,749	\$ 21,846
Convertible note payable, net of debt discount of \$85,890 at September 30, 2018	78,610	-
Accrued expenses	238,029	14,039
<b>Total Current Liabilities</b>	<u>356,388</u>	<u>35,885</u>
<b>Stockholders' Equity</b>		
Preferred stock; \$0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at September 30, 2018 (unaudited) and March 31, 2018	-	-
Common stock; \$0.00001 par value; 200,000,000 shares authorized; 10,677,110 and 10,499,610 issued and outstanding at September 30, 2018 (unaudited) and March 31, 2018, respectively	107	105
Additional paid in capital	3,538,900	3,054,297
Common stock to be issued, 212,000 and 263,000 shares at September 30, 2018 (unaudited) and March 31, 2018, respectively	537,852	526,000
Accumulated deficit	(3,407,857)	(2,901,933)
<b>Total Applied BioSciences Corp. Stockholders' Equity</b>	<u>669,002</u>	<u>678,469</u>
Non-controlling interest	(18,619)	(9,027)
<b>Total Stockholders' Equity</b>	<u>650,383</u>	<u>669,442</u>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<u>\$ 1,006,771</u>	<u>\$ 705,327</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**APPLIED BIOSCIENCES CORP.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

	<b>Three Months Ended September 30, 2018</b>	<b>Three Months Ended September 30, 2017</b>	<b>Six Months Ended September 30, 2018</b>	<b>Six Months Ended September 30, 2017</b>
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
<b>PRODUCT REVENUE, NET</b>	\$ 48,966	\$ 61,279	\$ 59,400	\$ 116,611
<b>COST OF REVENUE, PRODUCT</b>	<u>42,400</u>	<u>52,443</u>	<u>60,158</u>	<u>90,389</u>
<b>GROSS MARGIN (LOSS)</b>	<u>6,566</u>	<u>8,836</u>	<u>(758)</u>	<u>26,222</u>
<b>EXPENSES</b>				
Sales and marketing	111,393	45,496	455,437	65,061
General and administrative	188,052	84,619	395,198	223,516
Depreciation and Amortization	292	56,128	585	112,256
<b>TOTAL OPERATING EXPENSES</b>	<u>299,737</u>	<u>186,243</u>	<u>851,220</u>	<u>400,833</u>
<b>OPERATING LOSS</b>	(293,171)	(177,407)	(851,978)	(374,611)
<b>Other Income (Expense)</b>				
Unrealized gain on equity investments	245,834	-	404,763	-
Interest Expense	(66,422)	-	(68,301)	-
<b>Total other income, net</b>	<u>179,412</u>	<u>-</u>	<u>336,462</u>	<u>-</u>
<b>NET LOSS</b>	(113,759)	(177,407)	(515,516)	(374,611)
Less: Net loss (income) attributable to non controlling interest	<u>3,336</u>	<u>57</u>	<u>9,592</u>	<u>(1,139)</u>
<b>NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.</b>	<u>\$ (110,423)</u>	<u>\$ (177,350)</u>	<u>\$ (505,924)</u>	<u>\$ (375,750)</u>
<b>LOSS PER COMMON SHARE</b>	<u>\$ (0.01)</u>	<u>\$ (0.01)</u>	<u>\$ (0.05)</u>	<u>\$ (0.02)</u>
<b>WEIGHTED AVERAGE SHARES OUTSTANDING</b>				
Basic and diluted	<u>10,677,110</u>	<u>15,320,154</u>	<u>10,617,332</u>	<u>15,268,914</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**APPLIED BIOSCIENCES CORP.**  
**CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY**  
**FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2018 (UNAUDITED)**

	Common Stock \$0.00001 Par		Common Stock to be Issued	Additional Paid In Capital	Non- Controlling Interest	Accumulated Deficit	Stockholders' Equity
	Number	Amount					
Balance, March 31, 2018	10,499,610	\$ 105	\$ 526,000	\$3,054,297	\$ (9,027)	\$ (2,901,933)	\$ 669,442
Issuance of common stock previously committed but not issued	50,000	1	(100,000)	99,999			-
Issuance of common stock for cash	12,500		50,000	25,000			75,000
Fair value of shares issued to consultant for services	90,000	1	61,852	179,999			241,852
Fair value of shares issued to advisory board member	25,000	-		51,000			51,000
Beneficial conversion feature associated with a convertible note				128,605			128,605
Net loss					(9,592)	(505,924)	(515,516)
Balance, September 30, 2018 (unaudited)	<u>10,677,110</u>	<u>\$ 107</u>	<u>\$ 537,852</u>	<u>\$3,538,900</u>	<u>\$ (18,619)</u>	<u>\$ (3,407,857)</u>	<u>\$ 650,383</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**APPLIED BIOSCIENCES CORP.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

	<b>Six Months Ended September 30, 2018</b>	<b>Six Months Ended September 30, 2017</b>
	(unaudited)	(unaudited)
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net loss	\$ (515,516)	\$ (374,611)
Adjustment to reconcile net loss to net cash used in operating activities:		
Unrealized gain on equity investments	(404,763)	
Amortization of debt discount	42,715	-
Fair value of shares issued to consultants	255,352	50,000
Depreciation	586	-
Amortization of intangible	-	112,256
Changes in operating assets and liabilities		
Accounts receivable	1,321	(3,392)
Inventory	(22,598)	(7,648)
Prepaid and other current assets	107,500	1,382
Accounts payable and accrued expenses	241,893	11,805
Net cash used in operating activities	<u>(293,510)</u>	<u>(210,208)</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Acquisition of equity investment	-	(50,000)
Net cash used in investing activities	<u>-</u>	<u>(50,000)</u>
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>		
Issuance of convertible note	164,500	-
Issuance of common stock for cash	75,000	195,055
Net cash provided by financing activities	<u>239,500</u>	<u>195,055</u>
<b>NET CHANGE IN CASH</b>	(54,010)	(65,153)
<b>CASH, BEGINNING OF PERIOD</b>	<u>60,934</u>	<u>212,637</u>
<b>CASH, END OF PERIOD</b>	<u>\$ 6,924</u>	<u>\$ 147,484</u>
<b>NON-CASH INVESTING AND FINANCING ACTIVITIES</b>		
Fair value of shares issued to consultants recorded as prepaid	\$ 37,500	\$ -
Fair value of beneficial conversion feature related to issuance of convertible notes	\$ 128,605	\$ -
Increase in cash held in trust account from sale of common stock	<u>\$ -</u>	<u>\$ 499,945</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**APPLIED BIOSCIENCES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017**  
**(unaudited)**

**NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION**

**Description of the Company**

Applied BioSciences Corp. (formerly First Fixtures, Inc. and Stony Hill Corp. or the “Company”) was incorporated in the State of Nevada on February 21, 2014 and established a fiscal year end of March 31. Effective October 24, 2016 the Company changed its name from First Fixtures Inc. to Stony Hill Corp and on March 6, 2018, the Company changed its name from Stony Hill Corp. to Applied BioSciences Corp. The Company is focused on multiple areas of the hemp and CBD industry. Specifically, the Company is focused on select investments, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

**Basis of presentation – Unaudited Financial Statements**

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the rules and regulations of the Securities and Exchange Commission. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring adjustments, considered necessary for a fair presentation. Interim operating results are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2019, or for any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements as of and for the year ended March 31, 2018, which are included in the Company’s Report on Form 10-K for such year filed on June 28, 2018.

**Going concern**

These condensed statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As reflected in the condensed consolidated financial statements, the Company incurred a net loss of \$515,516 and used \$293,510 of cash in operating activities during the six months ended September 30, 2018. Further, the Company’s independent auditor in their audit report for fiscal year ended March 31, 2018 expressed substantial doubt about the Company’s ability to continue as a going concern. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

The Company’s ability to continue as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve sustainable revenues and income from operations. During the six months ended September 30, 2018, the Company sold 37,500 shares of its common stock to accredited investors at a price of \$2.00 per share for total proceeds of \$75,000 and issued three separate convertible notes for a total amount of \$164,500 both in private placements to accredited investors. However, the Company will need and is currently working on obtaining additional funds to operate its business through and beyond the date of this Form 10-Q filing. There is no assurance that such funds will be available or at terms acceptable to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions and covenants on its operations, in the case of debt financing or cause substantial dilution for its stockholders in the case of convertible debt and equity financing.

**APPLIED BIOSCIENCES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017**  
**(unaudited)**

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Principles of Consolidation**

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Applied Products LLC, VitaCBD LLC, an 80% owned entity, both Washington limited liability companies and SHL Management LLC, a Nevada limited liability company. Intercompany transactions and balances have been eliminated in consolidation. Management evaluates its investments on an individual basis for purposes of determining whether or not consolidation is appropriate.

**Reclassification of Certain Prior Year Information**

The Company has reclassified prior year sales and marketing expenses of \$45,496 and \$65,061 for the three and six months ended September 30, 2017, respectively, that were previously included in general and administrative expenses in the condensed consolidated statements of operations to conform to the current year presentation. The reclassification of sales and marketing expenses had no impact on net loss or cash flows.

**Use of Estimates and Assumptions**

Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, management estimates include the collectability of its accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.

**Revenue Recognition**

The Company adopted the guidance of ASC 606 on April 1, 2018, Revenue from Contracts with Customers (Topic 606), (ASC 606). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.

Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products or services to our customers based on written sales terms, which is also when control is transferred. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products or services to a customer.

The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.

**Advertising**

The Company expenses advertising costs as incurred. Advertising expense for the three and six months ended September 30, 2018 amounted to \$111,392 and \$455,437, respectively, and \$45,496 and \$65,061 for the three and six months ended September 30, 2017 and are included in “Sales and Marketing expenses” in the Condensed Consolidated Statements of Operations.

**APPLIED BIOSCIENCES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017**  
**(unaudited)**

**Earnings (Loss) per Share**

The basic earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by the weighted average number of common shares during the period. The diluted earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of dilutive items.

**Investments**

Through March 31, 2018, the Company used either the equity method or the cost method of accounting. The Company used the equity method for unconsolidated equity investments in which the Company was considered to have significant influence over the operations of the investee. The Company used the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, the Company writes down the cost basis of the investment to a new cost basis that represents realizable value.

On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, the Company measures its equity investments at their fair value at end of each reporting period.

Investments accounted for as above are included in the caption "Equity investments" on the Condensed Consolidated Balance Sheets.

**Recent Accounting Pronouncements**

In February 2016, the FASB issued ASU No. 2016-02, Leases. This update will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on its financial statements and related disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

**NOTE 3 – INVESTMENTS**

Equity investments relate to purchases of stock in certain entities with ownership percentages of less than 5%. As of March 31, 2018, these investments were recorded at their cost basis. On April 1, 2018, the Company adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities, and as such, these investments were recorded at their market value as of September 30, 2018. The investments consist of the following:

**APPLIED BIOSCIENCES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017**  
**(unaudited)**

	September 30, 2018	March 31, 2018
(A) Cannabi-Tech Ltd.	\$ 68,537	\$ 68,237
(B) Hightimes Holdings Corp.	654,763	250,000
(C) Precision Cultivation Systems, LLC	50,000	50,000
(D) Bailey Venture Partners XII LLC (JUUL)	100,000	100,000
	<u>\$ 873,300</u>	<u>\$ 468,537</u>

(A) In November 2016, the Company purchased 29,571 shares of Preferred A stock of Cannabi-Tech Ltd. (“Cannabi”), at a price of \$1.69086 per share for total investment of \$50,000. In October 2017, the Company purchased 7,309 shares of Preferred A-1 stock of Cannabi at a price of \$2.536 per share for total investment of \$18,537. As of March 31, 2018, total investment amounted to \$68,537, which accounts for less than 5% in Cannabi. Cannabi is a private company incorporated in the State of Israel that provides lab-grade medical cannabis quality control testing systems used to test the quality of medical marijuana flowers. The fair value of the investment at September 30, 2018 approximated its cost basis.

(B) In January 2017, the Company entered in to an agreement to purchase 59,524 shares of Class A common stock at a price of \$4.20 per share for total investment of \$250,000, which accounts for less than 5% investment in Hightimes Holdings Corp. (“Hightimes”). Hightimes owns Hight Times Magazine and hosts festivals, events and competitions including the High Times Cannabis Cup and multiple e-commerce properties, including HighTimes.com, CannabisCup.com and 420.com. As of September 30, 2018, the Company was able to obtain observable evidence that the investment had a market value of \$11.00 per share, or an aggregate value of \$654,763. As such, the Company recorded an unrealized gain from the change in market value of \$404,763 during the six months ended September 30, 2018.

(C) In June 2017, the Company entered in a Subscription Agreement to purchase 0.5% interest in Precision Cultivation Systems, LLC (“Precision”), a Delaware limited liability company, for a purchase price of \$50,000. Precision is developing a growth system that capitalizes on a patent-pending cultivation method that utilizes proprietary irrigation and root zone conditioning. As part of the Subscription Agreement, \$42,500 of the investment is subject to repayment on a pro-rata basis with other investors who have entered into similar Subscription Agreements. Amounts subject to repayment are solely at the discretion of Precision. The fair value of the investment at September 30, 2018 approximated its cost basis.

(D) In January 2018, the Company paid \$100,000 for the purchase of a Membership Interest in Bailey Venture Partners XII LLC (“Bailey”) representing less than 5% interest in Bailey. Along with other funds received from third-party investors, Bailey plans to invest funds received in various strategic investments. The Company recorded this investment at cost and will recognize dividends, if any, when received, and will recognize gains or loss upon either selling the securities or recognize a loss prior to selling the securities if there is evidence that the fair market value of the investment has declined to below the recorded historical cost. The fair value of the investment at September 30, 2018 approximated its cost basis.

As the Company does not participate in the management of these companies nor has the ability to exercise significant influence over these companies, the Company recorded these investments at cost, and as of April 1, 2018, will adjust the cost basis to market at the end of each reporting period. Dividends, if any, will be recognized when received.

#### **NOTE 4 – CONVERTIBLE NOTE**

During the six months ended September 30, 2018, the Company issued three separate Convertible Promissory Notes (“Notes”) having a total available principal amount of \$250,000 to the same holder of which the Company borrowed \$164,500 as of September 30, 2018. All outstanding principal together with interest on this Note is due and payable on December 31, 2018 and accrue interest at 8% per month. The note holder, at its sole discretion and election, may convert any part or all of the then outstanding principal and/or interest on these Notes into shares of common stock of the Company at a fixed price per share of \$1.00. As the conversion price of \$1.00 reflected a price discount below the fair market value of the Company’s common stock as of the date of the receipt of proceeds, there was deemed a beneficial conversion feature associated with these Notes. As such, the Company recorded \$128,605 in additional paid-in capital and debt discount representing the intrinsic value of the beneficial conversion feature at the date of the borrowing against the Notes. The value of the beneficial conversion feature is being amortized over the term of the Notes of which \$42,715 was amortized and reflected as interest expense for the six months ended September 30, 2018. As of September 30, 2018, the unamortized debt discount was \$85,890. As of September 30, 2018, the balance of the \$164,500 note, net of the unamortized discount of \$85,890 was \$78,610.

**APPLIED BIOSCIENCES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017**  
**(unaudited)**

**NOTE 5 – RELATED PARTY TRANSACTIONS**

In view of the Company's limited operations and resources, none of the Company's directors and/or officers received any compensation from the Company during the six months ended September 30, 2018.

**NOTE 6 – EQUITY**

Common Stock to be Issued

On February 23, 2017, the Company entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") with mCig, Inc., a Nevada corporation ("mCig") consisting of the issuance of an aggregate of 350,000 shares of common stock. Of the 350,000 shares of common stock consideration, 150,000 shares or \$426,000 have not been issued as of March 31, 2018 and have been included in "Common stock to be issued" in the accompanying condensed consolidated statement of stockholders' equity. During the six months ended September 30, 2018, the Company issued 50,000 shares of common stock valued at \$100,000 which was previously reflected as "Common stock to be issued" in the condensed consolidated statement of stockholders' equity.

During the six months ended September 30, 2018, the Company sold 37,500 shares of common stock, of which 25,000 shares had not been issued as of September 30, 2018 and is reflected in "Common stock to be issued" in the condensed consolidated statement of stockholders' equity. The shares were sold at a price of \$2.00 per share for total proceeds of \$75,000 pursuant to a private placement Subscription Agreement with accredited investors. The Subscription Agreement offered up to one million shares of the Company's common stock at a price per share of \$2.00 per share. The Company made this offering solely to accredited investors, as defined under Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended.

Establishment of Advisory Board and Adoption of Charter

On April 28, 2017, the Company established an advisory board (the "Advisory Board") and approved and adopted a charter (the "Advisory Board Charter") to govern the Advisory Board. The Advisory Board shall be comprised of one or more directors ("Advisors"), and up to nine independent, non-Board, non-employee members, all of whom shall be appointed and subject to removal by the Board of Directors at any time.

During the six months ended September 30, 2018, the Company appointed another Advisor to the Advisory Board, which entitled him to an annual consulting fee 25,000 shares of the Company's stock for a term of 6 months, with total fair value of \$51,000.

Shares Issued for Services

During the six months ended September 30, 2018, the Company granted an aggregate of 99,500 shares of its common stock to three (3) consultants as payment for services rendered to the Company and recorded expense of \$241,852 based on the fair value of the Company's common stock at grant dates. Of the 99,500 shares granted, 62,000 shares valued at \$61,852 had not been issued as of September 30, 2018, and were reflected in "Common stock to be issued" in the condensed consolidated statement of stockholders' equity during the period then ended.

**APPLIED BIOSCIENCES CORP.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE SIX MONTHS PERIODS ENDED SEPTEMBER 30, 2018 AND 2017**  
**(unaudited)**

**NOTE 7 – SUBSEQUENT EVENTS**

*Common Stock Purchase Agreement*

On October 15, 2018, the Company entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Triton Funds, LP, a Delaware limited partnership (the “Purchaser”), pursuant to which the Purchaser has the right to purchase up to \$1,000,000 of shares of common stock (the “Shares”) of the Company at a purchase price equal to 75% of the lowest closing price of the common stock of the Company on the over-the-counter markets for the five business days prior to a purchase. The Purchaser, however, will not have the right to purchase more than \$300,000 of common stock of the Company within a period of every 30 business days. The Company has the right to terminate the Purchase Agreement at any time, and the Purchase Agreement shall terminate automatically on June 30, 2019, unless earlier terminated. The Purchase Agreement also contains customary representations, warranties, and covenants by, among, and for the benefit of the parties.

On October 15, 2018, the Company entered into a non-binding letter agreement, pursuant to which the Company intends to issue 25,000 shares of common stock to the Purchaser, pursuant to a Share Donation Agreement to be entered into by and between the Company and the Purchaser at a future, unspecified date. The Company anticipates making the issuance of 25,000 shares on a date before December 31, 2018.

The Company’s offering of the Shares to the Purchaser is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Act (in that the Shares were offered by us in a transaction not involving any public offering) and pursuant to Rule 506 of Regulation D, promulgated thereunder.

**Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.**

This section of this Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

**Results of Operations**

Our revenue, operating expenses, and net loss from operations for our three and six months ended September 30, 2018 as compared to our three and six months ended September 30, 2017 were as follows:

**Three Months Ended September 30, 2018 Compared to Three Months Ended September 30, 2017**

	<b>Three Months Ended September 30, 2018</b>	<b>Three Months Ended September 30, 2017</b>	<b>\$ Change Inc (Dec)</b>	<b>Percentage Change Inc (Dec)</b>
<b>PRODUCT REVENUE, NET</b>	\$ 48,966	\$ 61,279	\$ (12,313)	(20)%
<b>COST OF REVENUE, PRODUCT</b>	42,400	52,443	(10,043)	(19)%
<b>GROSS (LOSS) MARGIN</b>	6,566	8,836	(2,270)	(26)%
<b>EXPENSES</b>				
Sales and marketing	111,393	45,496	65,897	145%
General and administrative	188,052	84,619	103,433	122%
Depreciation and Amortization	292	56,128	(55,836)	(99)%
<b>TOTAL OPERATING EXPENSES</b>	299,737	186,243	113,494	61%
<b>OPERATING LOSS</b>	(293,171)	(177,407)	115,764	65%
<b>Other Income (Expense)</b>				
Unrealized gain on equity investments	245,834	-	245,834	-
Interest Expense	(66,422)	-	(66,422)	-
<b>Total other income, net</b>	179,412	-	179,412	-
<b>NET LOSS</b>	(113,759)	(177,407)	(63,648)	(36)%
Less: Net loss attributable to non controlling interest	3,336	57	3,279	5753%
<b>NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.</b>	<b>\$ (110,423)</b>	<b>\$ (177,350)</b>	<b>\$ (66,927)</b>	<b>(38)%</b>

**Revenues:** Revenue from products relate to shipments of cannabidiol (“CBD”) brand products. During the three months ended September 30, 2018, we earned revenue from our CBD product lines of \$48,966 as compared to \$61,279 for the three months ended September 30, 2017. The decrease of \$12,313 relates to our efforts to replace then existing CBD products and change our product lines and branding to our new Remedi CBD, HerbalPet, TherPet and CanaGel CBD products. This required our change in marketing, branding, labeling and warehousing which ultimately caused sales to temporarily slow until we relaunched our new CBD products during our current fiscal year.

**Cost of Goods Sold:** Cost of goods sold consists of purchases of CBD product inventory for sale. During the three months ended September 30, 2018, we incurred \$42,400 of costs primarily related to product purchases and labeling of new products as compared to \$52,443 for the three months ended September 30, 2017. The decrease of \$10,043 reflects our refocus and launch of new products during our current fiscal year.

**Gross Margin:** Gross margin comprised from our sale of products and was \$6,566 for the three months ended September 30, 2018 as compared to \$8,836 for the three months ended September 30, 2017. The decrease of \$2,270 reflects our refocus and launch of new CBD products during our current fiscal year.

**Sales and Marketing:** Sales and marketing expenses mainly comprised of advertising, public relations, events, and website marketing costs. Sales and marketing expenses increased \$65,897 to \$111,393 for the three months ended September 30, 2018 as compared to \$45,496 for the three months ended September 30, 2017. The majority of the increase related to public relation services, website marketing development and increased advertising and promotion costs.

[Table of Contents](#)

**General and Administrative:** General and administrative expenses mainly comprised of professional fees, travel expenses, meals and entertainment and other office support costs. General and administrative expenses increased \$103,433 to \$188,052 for the three months ended September 30, 2018 as compared to \$84,619 for the three months ended September 30, 2017. The majority of the increase related to higher professional and advisory fees and other supportive general and administrative expenses.

**Depreciation and Amortization:** Depreciation expense was \$292 for the three months ended September 30, 2018 as compared to \$56,128 for the three months ended September 30, 2017. The decrease relates to amortization during our three months ended September 30, 2017 related to a brand that we acquired in February 2017, which was fully expensed during our fiscal year ended March 31, 2018. We did not own any similar intangibles that required amortization during the three months ended September 30, 2018.

**Unrealized Gain on Equity Investments:** During the three months ended September 30, 2018, we were able to obtain observable evidence that an investment we own had increased by \$4.13 per share for an aggregate value of \$654,763, which was \$245,834 higher than the fair value of this investment in the previous quarter. As such, we recorded an unrealized gain from the change in market value of \$245,834 during the three months ended September 30, 2018.

**Interest Expense:** During the three months ended September 30, 2018, we recorded \$66,422 of interest costs related to convertible notes that we entered into during our current fiscal year.

**Six Months Ended September 30, 2018 Compared to Six Months Ended September 30, 2017**

	<b>Six Months Ended September 30, 2018</b>	<b>Six Months Ended September 30, 2017</b>	<b>\$ Change Inc (Dec)</b>	<b>Percentage Change Inc (Dec)</b>
<b>PRODUCT REVENUE, NET</b>	\$ 59,400	\$ 116,611	\$ (57,211)	(49)%
<b>COST OF REVENUE, PRODUCT</b>	60,158	90,389	(30,231)	(33)%
<b>GROSS (LOSS) MARGIN</b>	(758)	26,222	(26,980)	(103)%
<b>EXPENSES</b>				
Sales and marketing	455,437	65,061	390,376	600%
General and administrative	395,198	223,516	171,682	77%
Depreciation and Amortization	585	112,256	(111,671)	(99)%
<b>TOTAL OPERATING EXPENSES</b>	<b>851,220</b>	<b>400,833</b>	<b>450,387</b>	<b>112%</b>
<b>OPERATING LOSS</b>	<b>(851,978)</b>	<b>(374,611)</b>	<b>477,367</b>	<b>127%</b>
<b>Other Income (Expense)</b>				
Unrealized gain on equity investments	404,763	-	404,763	-
Interest Expense	(68,301)	-	(68,301)	-
<b>Total other income, net</b>	<b>336,462</b>	<b>-</b>	<b>336,462</b>	<b>-</b>
<b>NET LOSS</b>	<b>(515,516)</b>	<b>(374,611)</b>	<b>140,905</b>	<b>38%</b>
Less: Net loss attributable to non controlling interest	9,592	(1,139)	10,731	942%
<b>NET LOSS ATTRIBUTABLE TO APPLIED BIOSCIENCES CORP.</b>	<b>\$ (505,924)</b>	<b>\$ (375,750)</b>	<b>\$ 130,174</b>	<b>35%</b>

**Revenues:** During the six months ended September 30, 2018, we earned revenue from our CBD product lines of \$59,400 as compared to \$116,611 for the six months ended September 30, 2017. The decrease of \$57,211 relates to our efforts to replace then existing CBD products and change our product lines and branding to our new Remedi CBD, HerbalPet, TherPet and CanaGel CBD products. This required our change in marketing, branding, labeling and warehousing which ultimately caused sales to temporarily slow until we relaunched our new CBD products during our current fiscal year.

## Table of Contents

**Cost of Goods Sold:** During the six months ended September 30, 2018, we incurred \$60,158 of costs primarily related to product purchases and labeling of new products as compared to \$90,389 for the six months ended September 30, 2017. The decrease of \$30,231 reflects our refocus and launch of new products during our current fiscal year.

**Gross (Loss) Margin:** Gross (loss) margin comprised from our sale of products and was a gross loss of \$758 for the six months ended September 30, 2018 as compared to a gross margin of \$26,222 for the six months ended September 30, 2017. The decrease of \$26,980 reflects our refocus and launch of new CBD products during our current fiscal year.

**Sales and Marketing:** Sales and marketing expenses increased \$390,376 to \$455,437 for the six months ended September 30, 2018 as compared to \$65,061 for the six months ended September 30, 2017. The majority of the increase related to public relation services, website marketing development and increased advertising and promotion costs.

**General and Administrative:** General and administrative expenses increased \$171,682 to \$395,198 for the six months ended September 30, 2018 as compared to \$223,516 for the six months ended September 30, 2017. The majority of the increase related to higher professional fees and general and administrative expenses.

**Depreciation and Amortization:** Depreciation expense was \$585 for the six months ended September 30, 2018 as compared to \$112,256 for the six months ended September 30, 2017. The decrease relates to amortization during our six months ended September 30, 2017 related to a brand that we acquired in February 2017, which was fully expensed during our fiscal year ended March 31, 2018. We did not own any similar intangibles that required amortization during the six months ended September 30, 2018.

**Unrealized Gain on Equity Investments:** During the six months ended September 30, 2018, we were able to obtain observable evidence that an investment we own had increased by \$6.80 per share for an aggregate value of \$654,763, which was \$404,763 higher than our original purchase price for this investment. As such, we recorded an unrealized gain from the change in market value of \$404,763 during the six months ended September 30, 2018.

**Interest Expense:** During the six months ended September 30, 2018, we recorded \$68,301 of interest costs related to a convertible notes that we entered into during the six months ended September 2018.

## **Liquidity and Capital Resources**

### **Cash Flows**

A summary of our cash flows for the six months ended September 30, 2018 is as follows:

Net cash used in operating activities was \$293,510 for the six months ended September 30, 2018 as compared to \$210,208 for the six months ended September 30, 2017. The increase in use of cash in operations mainly related to higher general and administrative and sales and marketing expenses from our operations.

Net cash used in investing activities was nil during the six months ended September 30, 2018 as compared to \$50,000 during the six months ended September 30, 2017, which comprised of a \$50,000 equity investment we made during that period.

Net cash provided by financing activities for the six months ended September 30, 2018 was \$239,500 as compared to \$195,055 for the six months ended September 30, 2017. The amounts received during our six months ended September 30, 2018 related to \$75,000 from proceeds from the sale of shares of our common stock and \$164,500 received from three convertible notes. The amounts received during our six months ended September 30, 2017 related to our issuance of our common stock for cash.

## [Table of Contents](#)

### **Going Concern**

As reflected in the condensed consolidated financial statements contained elsewhere in this Form 10-Q, as of September 30, 2018 we had cash on hand and had an accumulated deficit of \$6,924 and \$3,407,857, respectively, and during the six months ended September 30, 2018, we utilized cash for operations and incurred a net loss of \$293,510 and \$515,516, respectively. Our uses of cash have been primarily for strategic investments we made and operations and marketing efforts to promote and develop our CBD products and our company. Our principal sources of liquidity have been cash provided by financing, primarily through the sale of equity securities and issuance of convertible notes, along with revenues from our principal business activities. Further, we have used cash for various strategic investments for which we typically receive returns when such investments are sold and when or if dividends are declared.

As of the date of this Form 10-Q, our cash resources are insufficient to meet our current operating expense requirements and planned business objectives without additional financing. Our ability to continue as a going concern is dependent on our ability to raise additional capital and to ultimately achieve sustainable revenues and income from our operations. During the six months ended September 30, 2018, we raised \$75,000 through the receipt of Subscription Agreements (“Subscription”) where we sold 37,500 shares of our common stock to accredited investors at a price of \$2.00 per share. We also received during the six months ended September 30, 2018 \$164,500 from the issuance of convertible notes to an investor. However, we anticipate that significant additional expenditures will be necessary to expand and bring to market our products and investments before sufficient and consistent positive operating cash flows will be achieved. As such, we will need additional funds to operate our business through and beyond the date of this Form 10-Q filing.

To address our capital requirements, in October 2018 we entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Triton Funds, LP, a Delaware limited partnership (the “Purchaser”), pursuant to which the Purchaser has the right to purchase up to \$1,000,000 of our shares of common stock (the “Shares”) at a purchase price equal to 75% of the lowest closing price of our common stock on the over-the-counter markets for the five business days prior to a purchase. The Purchaser, however, will not have the right to purchase more than \$300,000 worth of our shares of common stock within a consecutive period of 30 business days. However, we anticipate that additional funds will be needed to continue operations, obtain profitability and to achieve our objectives. There can be no assurance that such funds will be available or at terms acceptable to us. Even if we are able to obtain additional financing, it may contain undue restrictions and covenants on our operations, in the case of debt financing or cause substantial dilution for our stockholders in the case of convertible debt and equity financing.

These and other factors raise substantial doubt about our ability to continue as a going concern. Further, our independent auditors in their audit report for our fiscal year ended March 31, 2018 expressed substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern.

### **Summary of Significant Accounting Policies**

#### **Use of Estimates**

Preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires us to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Among other things, our estimates include the collectability of our accounts receivable, recoverability of inventory, assumptions made in determining impairment of investments and intangible assets, accruals for potential liabilities, and realization of deferred tax assets. These estimates generally involve complex issues and require judgments, involve analysis of historical information and the prediction of future trends, and are subject to change from period to period. Actual amounts could differ significantly from these estimates.

## [Table of Contents](#)

### **Investments**

Through March 31, 2018, we used either the equity method or the cost method of accounting. We use the equity method for unconsolidated equity investments in which we are considered to have significant influence over the operations of the investee. We use the cost method for all other investments. Under the cost method, there is no change to the cost basis unless there is an other-than-temporary decline in value or dividends are received. If the decline is determined to be other-than-temporary, we write down the cost basis of the investment to a new cost basis that represents realizable value.

On April 1, 2018 we adopted ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 primarily affects equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Among other things, this new guidance requires certain equity investments to be measured at fair value with changes in fair value recognized in net income. As such, we measure our equity investments at their fair value at end of each reporting period.

Investments accounted for under the equity method or cost method of accounting above are included in the caption “Equity investments” in our Condensed Consolidated Balance Sheets.

### **Recent Accounting Pronouncements**

See our discussion of recent accounting policies in Footnote 2 to the condensed consolidated financial statements contained elsewhere in this Form 10-Q.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

### **Item 4. Controls and Procedures.**

#### **Disclosure Controls and Procedures**

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

In connection with this quarterly report, as required by Rule 15d-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of the design and operation of our company’s disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our company’s management, including our company’s principal executive officer and principal financial officer. Based upon that evaluation, our company’s principal executive officer and principal financial officer concluded that as of September 30, 2018, our disclosure controls and procedures were not effective.

#### **Changes in Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f)) during the six months ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

## PART II—OTHER INFORMATION

### Item 1. Legal Proceedings.

Currently we are subject to any pending litigation or legal proceeding.

### Item 1A. Risk Factors.

As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act we are not required to provide the information required under this item.

### Item 2. Unregistered Sales of Securities and Use of Proceeds.

Not applicable

### Item 3. Defaults Upon Senior Securities.

None.

### Item 4. Mine Safety Disclosures.

None.

### Item 5. Other Information.

On June 6, 2018, the Company offered and sold one convertible promissory note (the “Note”) in the principal amount of \$100,000. The note is due December 31, 2018, bears interest at 8% per month, and is convertible at any time, in the sole discretion of the holder of the Note, into shares of common stock of the Company at purchase price of \$1.00 per share. The Company made the offering to an “accredited investor” in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506, promulgated thereunder.

On August 1, 2018, the Company offered and sold one convertible promissory note (the “Second Note”) in the principal amount of \$100,000. The note is due December 31, 2018, bears interest at 8% per month, and is convertible at any time, in the sole discretion of the holder of the Second Note, into shares of common stock of the Company at purchase price of \$1.00 per share. The Company made the offering to an “accredited investor” in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506, promulgated thereunder.

[Table of Contents](#)

**Item 6. Exhibits.**

(a) Exhibits required by Item 601 of Regulation SK.

<b>Number</b>	<b>Description</b>
<a href="#">2.1</a>	<a href="#">Share Exchange Agreement, dated November 4, 2016, by and among the Applied Biosciences Corp., Stony Hill Ventures Corp., a Nevada corporation, and the holders of common stock of Stony Hill Ventures Corp. (3)</a>
<a href="#">3.1.1</a>	<a href="#">Articles of Incorporation (1)</a>
<a href="#">3.1.2</a>	<a href="#">Certificate of Amendment (3)</a>
<a href="#">3.1.3</a>	<a href="#">Certificate of Change (3)</a>
<a href="#">3.1.4</a>	<a href="#">Certificate of Amendment (4)</a>
<a href="#">3.2</a>	<a href="#">Bylaws (2)</a>
<a href="#">4.1</a>	<a href="#">Convertible Promissory Note, dated June 6, 2018</a>
<a href="#">4.2</a>	<a href="#">Convertible Promissory Note, dated August 1, 2018</a>
<a href="#">31.1</a>	<a href="#">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
<a href="#">31.2</a>	<a href="#">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
<a href="#">32.1</a>	<a href="#">Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
<a href="#">32.2</a>	<a href="#">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101.INS *	XBRL Instance Document
101.SCH *	XBRL Taxonomy Extension Schema Document
101.CAL *	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF *	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB *	XBRL Taxonomy Extension Label Linkbase Document
101.PRE *	XBRL Taxonomy Extension Presentation Linkbase Document

(1) Incorporated by reference to the Registrant's Registration Statement on Form S-1 (File No. 333-197443), filed with the Securities and Exchange Commission on July 16, 2014.

(2) Incorporated by reference to the Registrant's Registration Statement on Form S-1/A (File No. 333-197443), filed with the Securities and Exchange Commission on October 16, 2014.

(3) Incorporated by reference to the Registrant's Current Report on Form 8-K (File No. 000-52223), filed with the Securities and Exchange Commission on November 10, 2016.

(4) Incorporated by reference to the Registrant's Current Report on Form 8-K (File No. 000-52223) filed with the Securities Exchange Commission on March 5, 2018

\* XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**APPLIED BIOSCIENCES CORP.**  
(Name of Registrant)

Date: November 14, 2018

By: /s/ Chris Bridges  
Name: Chris Bridges  
Title: President (principal executive officer)

Date: November 14, 2018

By: /s/ John James Southard  
Name: John James Southard  
Title: Secretary and Treasurer (principal  
accounting officer and financial officer)

**This Promissory Note has not been registered with the Securities and Exchange Commission or the securities commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may not be offered or sold except pursuant to an effective registration statement under the securities act or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the securities act and in accordance with applicable state securities laws.**

**CONVERTIBLE PROMISSORY NOTE**

\$100,000

June 6, 2018

**APPLIED BIOSCIENCES CORP.**

Applied Biosciences Corp., a Nevada corporation (the “Company”), for value received, promises to pay to Grays Peak LLC, or any registered assigns (“Holder”) the sum of Hundred Thousand and 00/100 Dollars (\$100,000.00), together with interest thereon at the rate of eight percent (8%) per annum on the unpaid balance pursuant to this Convertible Promissory Note (“Note”). The Company shall make all payments to Holder at \_\_\_\_\_.

1. *Maturity Date; Interest Payments.* All outstanding principal together with interest on this Note shall be due December 31<sup>st</sup>, 2018, (“Maturity Date”).

2. *Conversion of Principal and Interest Owed.*

(a) Optional Conversion into Common Stock. The Holder, in its sole discretion and election, may convert any part or all of the outstanding principal and/or interest on this Note into shares of common stock of the Company obtained by dividing (i) any amount of part or all of the outstanding principal and/or interest on this Note, by (ii) \$ \_\_\_\_\_. If the Holder of this Note elects to make a conversion hereunder, then the Holder shall effect a conversion by delivering to the Company a completed Notice of Conversion, the form of which is attached hereto as Annex A, not later than three days after the date of conversion on such notice. Holder shall make delivery of such notice by way of e-mail attachment e-mailed to the President of the Company, provided receipt of such e-mail is confirmed by return e-mail by the President of the Company, or by delivery of the notice to: 9701 Wilshire Blvd., Suite 1000, Beverly Hills, California 90212.

3. *Registered Owner.* The Company may treat the person or persons whose name or names appear on this Note as the absolute owner or owners hereof for the purpose of receiving payment of, or on account of, the principal and interest due on this Note and for all other purposes.

4. *Representations and Warranties of the Company.*

(a) *Due Incorporation, Qualification, etc.* The Company (i) is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation; and (ii) has the power and authority to own, lease and operate its properties and carry on its business as now conducted.

(b) *Authority.* The execution, delivery and performance by the Company of this Note and the performance of the obligations contemplated hereby and thereby (i) are within the power of the Company and (ii) have been duly authorized by all necessary actions on the part of the Company.

(c) *Enforceability.* This Note has been duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.

(d) *Non-Contravention.* The execution and delivery by the Company of this Note and the performance of the obligations contemplated hereby does not and will not (i) violate any law, statute, rule or regulation applicable to the Company; (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other person to accelerate (whether after the giving of notice or lapse of time or both), the Certificate of Incorporation or Bylaws of the Company or any contract, agreement or instrument to which the Company is a party or by which any of its properties may be bound, or any order, decree or judgment binding upon the Company or any of its properties; or (iii) result in the creation or imposition of any lien or encumbrance upon any property or asset of the Company.

(e) *Approvals.* No consent, approval, order or authorization of, or registration, declaration, qualification or filing with, any governmental authority or other person is required in connection with the execution and delivery of the Note and the performance of the obligations contemplated hereby.

*5. Representations and Warranties of the Holder.*

(a) *No Public Sale or Distribution.* The Holder of this Note, by acceptance of this Note, agrees and acknowledges that such Holder is acquiring the Note for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under federal and state securities laws. Such Holder is acquiring the Note hereunder in the ordinary course of its business. Such Holder presently does not have any agreement or understanding, directly or indirectly, with any person to distribute the Note.

*6. Waivers and Acceleration.* The Company hereby waives diligence, presentment, protest, demand of payment, notice of protest, dishonor and nonpayment, and waives the legal effect of Holder's failure to give all notices not expressly provided for herein. All sums due under this Note shall, at the election of Holder, be immediately due and payable upon the happening of any one or more of the following events of default: (a) the Company defaults in the performance of or compliance with any term of this Note; (b) the Company makes a general assignment for the benefit of creditors; (c) the Company applies for or consents to the appointment of a receiver of the whole or any substantial part of the Company's assets; (d) the Company files a voluntary petition in bankruptcy or a petition or an answer seeking reorganization or an arrangement with creditors or to take advantage of any insolvency law or an answer admitting material allegations of a petition filed against the Company in any bankruptcy, reorganization or insolvency proceedings; or (e) an order, judgment, or decree is entered, without the application approval, or a consent of Company by any court of competent jurisdiction adjudging Company to be a bankrupt or approving a petition appointing a receiver, trustee, or liquidator of the whole or any substantial part of the assets of Company, and such order, judgment, or decree is not vacated or set aside or stayed within thirty (30) days from the date of its entry.

*7. Usury.* Notwithstanding any other provision of this Note to the contrary, all agreements between the Company and the Holder of this Note are expressly limited so that in no event or contingency shall the amount paid or agreed to be paid to the Holder of this Note for the use, forbearance or detention of the money to be advanced under this Note exceed the highest lawful rate permissible under applicable laws.

*8. Attorneys' Fees.* If any action at law or in equity is necessary to enforce or interpret the terms of this Note or the rights and duties of the parties in relation hereto, the prevailing party will be entitled, in addition to any other relief granted, to all costs and expenses incurred by any prevailing party, including, without limitation, all reasonable attorneys' fees. This note shall take effect as a sealed instrument and shall be construed, governed and enforced in accordance with the laws of the State of New York.

*9. Transfer of Note.* This Note may be transferred only upon surrender of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Holder shall provide the Company with prompt notice of any transfer of this Note; provided, however, that failure to provide such notice shall not void the transfer. Thereupon, a new Note for like principal amount will be issued to, and registered in the name of, the transferee.

THE COMPANY:

**APPLIED BIOSCIENCES CORP.**

By: /s/ John Brady

Name: John Brady

Title: Secretary

ANNEX A

**NOTICE OF CONVERSION**

The undersigned hereby elects to convert principal and/or interest under the Convertible Promissory Note due \_\_\_\_\_, of Applied Biosciences Corp., a Nevada corporation (the "Company"), into shares of common stock (the "Common Stock"), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.

The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock.

Conversion calculations:  
Date to Effect Conversion:

Principal Amount of Note to be Converted:

Payment of Interest in Common Stock  yes  no  
If yes, \$\_\_\_\_\_ of Interest Accrued on Account of Conversion at Issue.

Number of shares of Common Stock to be issued:

Signature:

Name:

DWAC Instructions:

Broker No: \_\_\_\_\_  
Account  
No: \_\_\_\_\_

**This Promissory Note has not been registered with the Securities and Exchange Commission or the securities commission of any state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may not be offered or sold except pursuant to an effective registration statement under the securities act or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the securities act and in accordance with applicable state securities laws.**

**CONVERTIBLE PROMISSORY NOTE**

\$100,000

August 1, 2018

**APPLIED BIOSCIENCES CORP.**

Applied Biosciences Corp., a Nevada corporation (the "Company"), for value received, promises to pay to Grays Peak LLC, or any registered assigns ("Holder") the sum of Hundred Thousand and 00/100 Dollars (\$100,000.00), together with interest thereon at the rate of eight percent (8%) per month on the unpaid balance pursuant to this Convertible Promissory Note ("Note"). The Company shall make all payments to Holder at \_\_\_\_\_.

1. *Maturity Date; Interest Payments.* All outstanding principal together with interest on this Note shall be due December 31<sup>st</sup>, 2018, ("Maturity Date").

2. *Conversion of Principal and Interest Owed.*

(a) Optional Conversion into Common Stock. The Holder, in its sole discretion and election, may convert any part or all of the outstanding principal and/or interest on this Note into shares of common stock of the Company obtained by dividing (i) any amount of part or all of the outstanding principal and/or interest on this Note, by (ii) \$1.00. If the Holder of this Note elects to make a conversion hereunder, then the Holder shall effect a conversion by delivering to the Company a completed Notice of Conversion, the form of which is attached hereto as Annex A, not later than three days after the date of conversion on such notice. Holder shall make delivery of such notice by way of e-mail attachment e-mailed to the President of the Company, provided receipt of such e-mail is confirmed by return e-mail by the President of the Company, or by delivery of the notice to: 9701 Wilshire Blvd., Suite 1000, Beverly Hills, California 90212.

3. *Registered Owner.* The Company may treat the person or persons whose name or names appear on this Note as the absolute owner or owners hereof for the purpose of receiving payment of, or on account of, the principal and interest due on this Note and for all other purposes.

4. *Representations and Warranties of the Company.*

(a) *Due Incorporation, Qualification, etc.* The Company (i) is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation; and (ii) has the power and authority to own, lease and operate its properties and carry on its business as now conducted.

(b) *Authority.* The execution, delivery and performance by the Company of this Note and the performance of the obligations contemplated hereby and thereby (i) are within the power of the Company and (ii) have been duly authorized by all necessary actions on the part of the Company.

(c) *Enforceability.* This Note has been duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors' rights generally and general principles of equity.

(d) *Non-Contravention.* The execution and delivery by the Company of this Note and the performance of the obligations contemplated hereby does not and will not (i) violate any law, statute, rule or regulation applicable to the Company; (ii) violate any provision of, or result in the breach or the acceleration of, or entitle any other person to accelerate (whether after the giving of notice or lapse of time or both), the Certificate of Incorporation or Bylaws of the Company or any contract, agreement or instrument to which the Company is a party or by which any of its properties may be bound, or any order, decree or judgment binding upon the Company or any of its properties; or (iii) result in the creation or imposition of any lien or encumbrance upon any property or asset of the Company.

(e) *Approvals.* No consent, approval, order or authorization of, or registration, declaration, qualification or filing with, any governmental authority or other person is required in connection with the execution and delivery of the Note and the performance of the obligations contemplated hereby.

5. *Representations and Warranties of the Holder.*

(a) *No Public Sale or Distribution.* The Holder of this Note, by acceptance of this Note, agrees and acknowledges that such Holder is acquiring the Note for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under federal and state securities laws. Such Holder is acquiring the Note hereunder in the ordinary course of its business. Such Holder presently does not have any agreement or understanding, directly or indirectly, with any person to distribute the Note.

6. *Waivers and Acceleration.* The Company hereby waives diligence, presentment, protest, demand of payment, notice of protest, dishonor and nonpayment, and waives the legal effect of Holder's failure to give all notices not expressly provided for herein. All sums due under this Note shall, at the election of Holder, be immediately due and payable upon the happening of any one or more of the following events of default: (a) the Company defaults in the performance of or compliance with any term of this Note; (b) the Company makes a general assignment for the benefit of creditors; (c) the Company applies for or consents to the appointment of a receiver of the whole or any substantial part of the Company's assets; (d) the Company files a voluntary petition in bankruptcy or a petition or an answer seeking reorganization or an arrangement with creditors or to take advantage of any insolvency law or an answer admitting material allegations of a petition filed against the Company in any bankruptcy, reorganization or insolvency proceedings; or (e) an order, judgment, or decree is entered, without the application approval, or a consent of Company by any court of competent jurisdiction adjudging Company to be a bankrupt or approving a petition appointing a receiver, trustee, or liquidator of the whole or any substantial part of the assets of Company, and such order, judgment, or decree is not vacated or set aside or stayed within thirty (30) days from the date of its entry.

7. *Usury.* Notwithstanding any other provision of this Note to the contrary, all agreements between the Company and the Holder of this Note are expressly limited so that in no event or contingency shall the amount paid or agreed to be paid to the Holder of this Note for the use, forbearance or detention of the money to be advanced under this Note exceed the highest lawful rate permissible under applicable laws.

8. *Attorneys' Fees.* If any action at law or in equity is necessary to enforce or interpret the terms of this Note or the rights and duties of the parties in relation hereto, the prevailing party will be entitled, in addition to any other relief granted, to all costs and expenses incurred by any prevailing party, including, without limitation, all reasonable attorneys' fees. This note shall take effect as a sealed instrument and shall be construed, governed and enforced in accordance with the laws of the State of New York.

9. *Transfer of Note.* This Note may be transferred only upon surrender of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Holder shall provide the Company with prompt notice of any transfer of this Note; provided, however, that failure to provide such notice shall not void the transfer. Thereupon, a new Note for like principal amount will be issued to, and registered in the name of, the transferee.

THE COMPANY:

**APPLIED BIOSCIENCES CORP.**

By: /s/ John Brady

Name: John Brady

Title: Secretary

ANNEX A

**NOTICE OF CONVERSION**

The undersigned hereby elects to convert principal and/or interest under the Convertible Promissory Note due \_\_\_\_\_, of Applied Biosciences Corp., a Nevada corporation (the "Company"), into shares of common stock (the "Common Stock"), of the Company according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.

The undersigned agrees to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares of Common Stock.

Conversion calculations:  
Date to Effect Conversion:

Principal Amount of Note to be Converted:

Payment of Interest in Common Stock  yes  no  
If yes, \$\_\_\_\_\_ of Interest Accrued on Account of Conversion at Issue.

Number of shares of Common Stock to be issued:

Signature:

Name:

DWAC Instructions:

Broker No:  
Account No:

**SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER OF APPLIED BIOSCIENCES  
CORP.**

I, Chris Bridges, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Applied Biosciences Corp.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2018

By: /s/ Chris Bridges  
Chris Bridges  
President (principal executive officer)

**SECTION 302 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF APPLIED BIOSCIENCES  
CORP.**

I, John James Southard, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Applied Biosciences Corp.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2018

By: /s/ John James Southard  
John James Southard  
Secretary (principal accounting officer  
and principal financial officer)

**SECTION 906 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER OF APPLIED BIOSCIENCES  
CORP.**

In connection with the accompanying Quarterly Report on Form 10-Q of Applied Biosciences Corp. for the six months ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Chris Bridges, President of Applied Biosciences Corp., does hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Applied Biosciences Corp.

Date: November 14, 2018

By: */s/ Chris Bridges*

Chris Bridges

President

(principal executive officer)

**SECTION 906 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF APPLIED BIOSCIENCES  
CORP.**

In connection with the accompanying Quarterly Report on Form 10-Q of Applied Biosciences Corp. for the six months ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, John James Southard, Secretary of Applied Biosciences Corp., does hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Applied Biosciences Corp.

Date: November 14, 2018

By: */s/ John James Southard*  
John James Southard  
Secretary and Treasurer  
(principal accounting officer and principal  
financial officer)